{"id":"NCT00915772","sponsor":"Boehringer Ingelheim","briefTitle":"Treatment of Type 2 Diabetes With Linagliptin 2.5 mg Bid + Metformin 500 or 1000 mg Bid and Metformin 1000 mg Bid","officialTitle":"Extension Study Linagliptin 2.5 mg Bid + Metformin 500 or 1000 mg Bid Versus Metformin 1000 mg Bid","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-06","primaryCompletion":"2011-06","completion":null,"firstPosted":"2009-06-08","resultsPosted":"2012-07-18","lastUpdate":"2014-05-14"},"enrollment":567,"design":{"allocation":"RANDOMIZED","model":"SINGLE_GROUP","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"Linagliptin + metformin","otherNames":[]},{"type":"DRUG","name":"Linagliptin+metformin","otherNames":[]},{"type":"DRUG","name":"Metformin","otherNames":[]}],"arms":[{"label":"Linagliptin + metformin bid","type":"EXPERIMENTAL"},{"label":"Linagliptin+ metformin bid","type":"EXPERIMENTAL"},{"label":"Metformin bid","type":"ACTIVE_COMPARATOR"}],"summary":"A phase III randomised, double-blind parallel group extension study to investigate the efficacy and safety of twice daily administration of the free combination of linagliptin 2.5 mg + metformin 500 mg or of linagliptin 2.5 mg + metformin 1000 mg versus monotherapy with metformin 1000 mg twice daily over 54 weeks in type 2 diabetic patients previously completing the double-blind part of study 1218.46","primaryOutcome":{"measure":"Frequency of Patients With Adverse Events (AEs)","timeFrame":"54 weeks","effectByArm":[{"arm":"M1000","deltaMin":124,"sd":null},{"arm":"L2.5+M500","deltaMin":149,"sd":null},{"arm":"L2.5+M1000","deltaMin":132,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":7},"locations":{"siteCount":112,"countries":["Canada","Croatia","Estonia","France","Germany","India","Lithuania","Mexico","Netherlands","Romania","Russia","Sweden","Tunisia","Ukraine"]},"refs":{"pmids":[],"seeAlso":["http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1218/1218.52_Literature.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":170},"commonTop":["Hyperglycaemia","Diabetes mellitus","Glomerular filtration rate decreased","Nasopharyngitis","Hypertension"]}}